newsfilter
← Latest News
ClinicalTrials.gov·

ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer - NCT05824559

Progression Free Survival (PFS) rate at 16 weeks, Overall Response Rate (ORR), Safety and tolerability of ME-344 administered in combination with bevacizumab